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Multiple myeloma remains an incurable disease although the prognosis has been improved by novel therapeutics and agents
recently. Relapse occurs in the majority of patients and becomes fatal ﬁnally. Immunotherapy might be a powerful intervention to
maintainalong-lastingcontrolofminimalresidualdiseaseortoeveneradicatedisseminatedtumorcells.Severaltumor-associated
antigens have been identiﬁed in patients with multiple myeloma. These antigens are expressed in a tumor-speciﬁc or tumor-
restricted pattern, are able to elicit immune response, and thus could serve as targets for immunotherapy. This review discusses
immunogenic antigens with therapeutic potential for multiple myeloma.
1.Introduction
Multiple myeloma (MM) will account for an estimated
20,180 new cancer cases in the United States in 2010, in-
cluding 11,170 cases in men and 9,010 cases in women,
with an estimated 10,650 deaths [1]. The implementation of
autologous stem-cell transplantation and novel agents such
as thalidomide, lenalidomide, and bortezomib has changed
the management of myeloma and extended overall survival
[2–4]. The 5-year survival rate reported in the Surveillance
Epidemiology and End Results database has increased from
25% in 1975 to 34% in 2003 owing to those newer and
more eﬀective treatment options available [5, 6]. However,
patients invariably relapse even if complete remission is
achieved. Patients in relapse, usually in old ages [7]a n d
having experienced a long term of treatment, have poor
tolerability to further intervention, whereas the myeloma
cells have acquired resistance to previous therapy and are
very likely cross-resistant to similar drugs. Therefore, the
ﬁnal outcome of patients with MM is sad, and MM still
remains an incurable disease. Novel therapeutics are still
being expected to further improve the outcome of patients
with MM.
Antitumorimmunotherapyisprovedtobewell-tolerated
and thought to be unlikely cross-resistant with current drugs
and thus might be a powerful intervention to maintain a
long-lasting control of minimal residual disease or to even
eradicate disseminated tumor cells [8, 9]. Some immuno-
therapies have achieved clinical success and have been
approved for clinical use in tumors, employing monoclonal
antibodies or immune cells. For example, rituximab, an anti-
CD20 antibody, has extended survival of patients with B-cell
non-Hodgkin’s lymphoma (NHL). Medication of rituximab
as single treatment or in combination with chemotherapy
has been a standard treatment for NHL. [10, 11]. Sipuleucel-
T is an active cellular immunotherapy consisting of autolo-
gousPBMCspulsedinvitrowithatumor-associatedantigen.
Beneﬁt from Sipuleucel-T was conﬁrmed in patients with
castration-resistant prostate cancer by a phase III random-
ized trial [12] and Sipuleucel-T has become the ﬁrst cellular
therapeutic for solid tumors approved by FDA. However,
immunotherapy with unequivocal clinical beneﬁt is not
established yet in MM. Several tumor-associated antigens
have been identiﬁed in patients with MM. Some of them
are expressed in a tumor-speciﬁc or tumor-restricted pattern
and are able to elicit immune response. Thus, they might2 Clinical and Developmental Immunology
be the candidate of targets for immunotherapy. This review
discusses immunogenic antigens which are present in MM
and have therapeutic potential for patients with MM.
2. Targets for Speciﬁc Immunotherapy in MM
2.1. Immunogenic Antigens. A few but growing number of
immunogenic antigens have been discovered in MM, includ-
ing idiotypes on MM immunoglobulin, MUC1, WT1, a
subgroup of cancer-testis antigens (CTAs), receptor for hy-
aluronic acid-mediated motility (RHAMM), Dickkopf1
(DKK1)andHM1.24.Idiotypereferstotheuniqueimmuno-
logical properties of any individual immunoglobulin. Nor-
mally each B-cell clone synthesizes one certain type of im-
munoglobulin which is unique to the B-cell. As MM is
a clonal B-cell malignancy, idiotype has been considered
a tumor-speciﬁc and even individual-speciﬁc antigen [53].
The other immunogenic antigens are shared with other solid
tumors or hematologic malignancies. These antigens are able
to elicit humoral and cellular immune reactions in patients
with MM (discussed below), and most of them are linked to
cellcycleorproliferation[13,17,22,26,35,39,45](Table 1).
Therefore, these antigens are considered competent target
structures for immunotherapy.
2.2. Immunotargets Expressed in MM. The expression of
those immunogenic antigens mentioned above is frequent in
MM cells and restricted in normal tissue, which is very
suitable for immunotargets. Idiotype [13], RHAMM [36],
DKK1 [39, 40], and HM1.24 [46] are expressed in almost
all MM patients; MUC1 [18], WT1 [23], and MAGE-C1
[27–30] are expressed in the majority of MM patients and
ropporin is detected in about 44% of MM patients [33].
In normal tissue their expression is restricted [13, 24, 31,
34, 35, 40, 41, 46], with the exception of MUC1. MUC1
is ubiquitously expressed on the luminal surface of most
simple epithelial cells. However, on malignant cells MUC1
is overexpressed and aberrantly glycosylated [19]a n dt h u s
can be distinguished from MUC1 on normal cells. Notably,
HM1.24 had been thought to be preferentially expressed on
terminally diﬀerentiated B-cells and overexpressed on MM
cells, but not or slightly expressed in other normal tissues
[46]. However, a recent report questioned the expression
pattern of HM1.24 and the rationality of HM1.24 as a
target for immunotherapy. Erikson et al. investigated the
expression of HM1.24 by tissue microarray and found that
it was expressed in a number of normal cell types including
hepatocytes, pneumocytes, pancreas and kidney, epithelia,
monocytes,andvascularendothelium[45].Thisdiscrepancy
in expression proﬁle was ascribed to diﬀerences in the
sensitivity of immunodetection. Resulting from this, the
expression proﬁle of HM1.24 and the safety of HM1.24
targeting immunotherapy need to be reconsidered.
2.3. Speciﬁc Immune Response against Immunogenic Antigens
in MM. As the ﬁrst identiﬁed tumor-associated antigen
in MM, idiotype has been proved to be immunogenic by
plenty of experiments, and the immunogenicity was further
conﬁrmed in clinical trials [13–16]. An HLA-A2-restricted
peptide derived from MUC1 was used to pulse dendritic
cells (DCs) and generated speciﬁc cytotoxic T lymphocytes
(CTLs). These speciﬁc CTLs exhibited cytotoxicity against
a myeloma cell line expressing MUC1. Another peptide de-
rived from hTERT also showed a similar eﬀect in this exper-
iment [21]. Spontaneous formation of antibodies against
MUC1 was reported in MM patients, although at a low level
[20].
CTA-speciﬁc immune responses were also reported in
MM patients. Spontaneous antibodies and T lymphocytes
directed against NY-ESO-1 were detected in MM patients.
After being expanded by autologous antigen presenting cells
(APCs) pulsed with NY-ESO-1-derived peptide analog, the
speciﬁc CTLs were able to lyse primary MM cells [54].
Ropporin is a novel CTA identiﬁed in 2007 [34]. Speciﬁc
antibodies were detected in the serum of all patients who
showed ropporin protein staining in immunocytochemistry.
Furthermore, ropporin protein was proved to be located on
the surface of MM cells, suggesting that ropporin could be
exploited as a target for antibody therapy. Moreover, speciﬁc
CTLs were generated by incubation with autologous DCs
loaded with ropporin and showed cytolytic eﬀect against au-
tologous MM cells [33].
MAGE-C1 is the most commonly expressed CTA in
MM. Recently several studies investigated the immuno-
genicity of MAGE-C1 in MM patients. Lendvai et al. ﬁrst
described CD8+ T-cell reactions against MAGE-C1, which
were detected in MM patients, and these CD8+ T-cell re-
sponses were restricted to patients expressing MAGE-C1
mRNA in their CD138+ myeloma cells. However, the sample
size of this study was small, and more extended data
from further samples have to be generated [26]. HLA-A2-
restricted epitopes have been identiﬁed from MAGE-C1,
and speciﬁc CD8+ T cells were able to recognize MAGE-C1
expressing myeloma cells [31], which may facilitate develop-
ment of immunotherapy targeting MAGE-C1. CD4+ T-cell
reactions against MAGE-C1, which are indispensable for a
robust immune eﬀect, were also reported, although not yet
in MM patients [55]. In addition, speciﬁc antibodies against
MAGE-C1 were detected in 50% of MM patients and in
nearly all patients with MAGE-C1 expressing myeloma cells,
demonstrating a high immunogenicity of epitopes derived
from MAGE-C1 [32]. However, in the study of Lendvai et al.,
simultaneous humoral immune responses were not detected,
probably because of the small sample size [26].
Dickkopf1 (DKK1) is a secreted protein that hampers
bone formation by inhibiting the Wnt/β-catenin pathway
and thus contributes to osteolytic bone disease in MM [56].
Qian et al. identiﬁed HLA-A2-restricted peptides from
DKK1 and proved the immunogenicity by vaccinating HLA-
A∗0201 transgenic mice. Corresponding speciﬁc CTL pre-
cursor cells were detected in MM patients, although at a
low frequency. Stimulation by autologous DCs loaded with
DKK1 peptides generated speciﬁc T cells which were able
to lyse DKK1-expressing cells including autologous primary
MM cells, in an HLA-A2 restricted manner [40]. In another
recent report, the eﬃciency of DKK1-DNA vaccine was
examined in a murine MM model. The vaccination elicited
a strong and speciﬁc CD4+ and CD8+ T-cell response.Clinical and Developmental Immunology 3
Table 1: Expression proﬁle and immune responses of promising immunotargets in MM.
Antigen Function Expression in MM Expression in
normal tissue
Humoral
response in
MM
CD8+ T-cell
response in
MM
CD4+ T-cell
response in
MM
Clinical trials
in MM
Idiotype
Essential for B-cells
function and
survival [13]
Nearly 100% [13]B - c e l l s [ 13]Y e s [ 14]Y e s [ 13, 15]Y e s [ 15]
PhaseI-II,clin-
ical response
was disap-
pointing [16]
MUC1
Multiple functions
including surface
barrier, signal
transduction, and
so forth [17]
Fully glycosylated: 73%
Diﬀerentiation-dependent
glycoforms: 59%
Cancer-associated
glycoforms: 36% [18]
Ubiquitous on
the luminal
surface of most
simple epithelial
cells [19]
Yes [20]Y e s [ 21]Y e s [ 21]N D
WT1 Transcription
factor [22]
Frequent but at a low level
[23] Placenta [24]N DY e s [ 25]N D
One patient re-
ported, show-
ing decreased
myeloma cells
[25],
MAGE-C1
Probably
dysregulation of
the cell cycle [26]
70–80% [27–30] Testis, placenta
[31] Yes [32]Y e s [ 26]N D N D
Ropporin Unknown 44% [33]T e s t i s [ 34]Y e s [ 34]Y e s [ 33]N D N D
RHAMM
Formation of
mitotic spindle,
signal transduction
[35]
100% [36] Testis, placenta,
thymus [24, 35] ND Yes [37, 38]N D
Two phase I/II
peptide vacci-
nation trials,
including 7
MM patients,
with three
showing clini-
cal response
[37, 38]
DKK1
Inhibitor of
osteoblast
diﬀerentiation [39]
Almost all patients [40]
Placenta,
prostate and
testis [40, 41]
Yes [42, 43]Y e s [ 40, 44]Y e s [ 44]N D
HM1.24
Antiviral
restriction factor
[45]
100% [46]
Terminally
diﬀerentiated
B-cells∗ [46]
Yes [47–49]Y e s [ 50–52]N D N D
∗The expression of HM1.24 in normal tissue needs to be further investigated.
ND: No data available.
Moreover, the vaccine was able to protect mice from MM
challenge and exhibited therapeutic eﬀect against established
MM [44]. Two anti-DKK1 neutralizing antibodies have been
tested as therapeutic agents in mice bearing human primary
MM. Both antibodies reduced osteolytic bone resorption
and increased bone formation, indicating their potential
application for the palliative treatment. Furthermore, the
two antibodies also inhibited myeloma cell growth in vivo,
probablythroughblockageofbonemarrowstromalcell/MM
cell adhesion and production of IL-6 [42, 43].
HM1.24 antigen (also referred to as CD317, BST2, or
tetherin) is a surface molecule involved in controlling virus
infection [45]. HM1.24-loaded DCs were able to induce
speciﬁc CTLs in vitro from peripheral blood of healthy
volunteers and MM patients. The speciﬁc CTLs showed the
ability to recognize and lyse myeloma cells [50–52]. Several
HLA I-restricted epitopes within HM1.24 have been iden-
tiﬁed and proved to be of potent immunogenicity [52, 57].
More evidence of humoral immune responses is available by
targeting HM1.24. A humanized anti-HM1.24 monoclonal
antibody has been developed and has exhibited antimyeloma
eﬀect by inducing antibody-dependent cellular cytotoxicity
(ADCC) [47]. Injection of this antibody inhibited tumor
growth, reduced tumor load, and prolonged survival of
myeloma-bearing mice in xenograft mouse model [48].
Defucosylation could further enhance the ADCC against
primary myeloma cells [49].
2.4. Clinical Trials against Immunotargets. Idiotype, WT1,
and RHAMM have been tested as therapeutic targets in
published clinical trials. Several studies have investigated
the use of idiotype protein or peptide pulsed DCs as
vaccine for patients with MM [16]. Immune responses were
evoked in some patients, but clinical responses were rare.
This unsatisfactory outcome of idiotype vaccination in MM
was partially due to the weak immunogenicity of idiotype4 Clinical and Developmental Immunology
proteins [58]. Diﬀerent approaches are under clinical eval-
uation for enhancing idiotype-targeted immune response
[59, 60].
WT1 peptide-based vaccination was performed in a pa-
tient with advanced chemotherapy-resistant MM. The fre-
quency of WT1 speciﬁc CTLs increased after vaccination.
Myeloma cells in BM decreased from 85% to 25%, and the
amount of M protein in the urine decreased from 3.6 to
0.6g/day. A bone scintigram showed improvement of bone
lesions, especiallyof the ribs, so that the clinical response was
assessed as minimal (EGBMT criteria) [25].
HLA-A2-restricted epitopes within RHAMM have been
identiﬁed [61], and the most robust one, which was des-
ignated R3, was tested in clinical peptide vaccination trials
in patients with acute myeloid leukemia, myelodysplastic
syndrome, and MM. Seven patients with MM were recruited
and exhibited exciting results. Immune responses were
observed in 6/7 (85.7%) patients and three of them showed
a positive clinical eﬀect, which was manifested by reduction
of free light chain serum levels [37, 38]. The high frequency
of immune responses and clinical responses indicates that
RHAMM could be a promising target for T-cell therapy
against MM.
Furthermore, several clinical trials are ongoing to inves-
tigate the vaccination eﬀect of NY-ESO-1 or MAGE-A3 pep-
tide with GM-CSF (NCT00090493), MUC1 peptide with
GM-CSF (NCT01232712), or idiotype-KLH and T-cells
(NCT01426828) in MM patients (http://www.clinicaltrials
.gov/).Theseclinicaltrialswillyieldmoreevidenceofspeciﬁc
immunotherapy for MM using diﬀerent targets.
3.FuturePerspectives
Diﬀerent immunogenic targets expressed in MM have to
be evaluated in future clinical trials to detect their clinical
relevance.CandidatescouldbeantigensidentiﬁedfromMM,
or antigens which have shown therapeutic potential in other
malignancies like MUC1 and WT1. CD4+ T-cell activation,
which is indispensable for inducing eﬃcient immune eﬀect,
was described for idiotype [15], MUC1 [21], and DKK1
[44] in MM. Therefore, the ability to stimulate CD4+ T-cells
and the corresponding epitopes of the immunogenic targets
need to be further investigated. Adjuvants help breaking
immune tolerance in MM patients and enhance immune
eﬀects, but the optimal adjuvant has to be established for
individual antigens [59]. Bivalent or multivalent vaccines
against diﬀerent antigens might be another strategy to
strengthen immune response and prevent immune evasion.
4. Summary
There is an urgent need for novel therapeutics to improve
the outcome of patients with MM. An increasing number
of immunogenic antigens have been discovered in MM and
thus open the possibility to develop speciﬁc immunotherapy
for MM. Some of them have been tested in clinical vaccina-
tion trials and generated important results. Immunotherapy
targeting these antigens might be a promising approach to
reduce or delay relapse, and thus improve outcome of MM.
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